NCT05388305
Universal CAR-γδT Cell Injection in the AML Patients
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Refractory and Relapsed AML Patients
Hebei Senlang Biotechnology Inc., Ltd.·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- AML
- Drug/Device/Intervention
- CAR--γδT cells
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Location
- Wuhan, China
Timeline & enrollment
- Phase
- N/A
- Start date
- Apr 20, 2022
- End date
- May 30, 2023
- Enrollment
- 30 participants
Primary outcome
Safety: Incidence and severity of adverse events
Summary
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory
 post-transplant relapsed AML.
ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05388305
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05388305 through Pure Global AI's free database. This phase not specified trial is sponsored by Hebei Senlang Biotechnology Inc., Ltd. and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.